PDCD1 and melanoma: In patients with previously untreated metastatic or un-resectable melanoma, combination of relatlimab (anti-LAG3 antibody) and nivolumab (anti-PD-1 antibody) has increased the median progression-free survival more than two times when compared to PD-1 inhibition alone (Tawbi et al. 2022).